---
title: "TuHURA Biosciences, Inc. 1Q 2026: Revenue $0 Net loss $(7.54M), EPS $(0.13) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286619051.md"
description: "TuHURA Biosciences, Inc. reported Q1 2026 results with $0 revenue and a net loss of $(7.54M), compared to $(6.67M) in Q1 2025. The company initiated a Phase 3 trial for IFx-2.0 and expanded its pipeline with the acquisition of Kineta. They launched a $50M market program and secured funding for development. R&D efforts are focused on IFx-2.0 and TBS-2025, while discontinuing IFx-3.0."
datetime: "2026-05-15T21:31:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286619051.md)
  - [en](https://longbridge.com/en/news/286619051.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286619051.md)
---

# TuHURA Biosciences, Inc. 1Q 2026: Revenue $0 Net loss $(7.54M), EPS $(0.13) — 10-Q Summary

TuHURA Biosciences, Inc. reported first-quarter 2026 results showing no product revenue and a wider net loss versus the prior-year quarter as the company ramps clinical and R&D programs tied to its immunotherapy pipeline.

**Financial Highlights**

-   Revenue: $0 for Q1 2026 and Q1 2025 (no product revenue reported).
-   Net income: Net loss attributable to common stockholders of $(7.54M) for Q1 2026 versus net loss $(6.67M) for Q1 2025 (≈ $(0.87M) change YoY).
-   Diluted EPS: $(0.13) for Q1 2026 versus $(0.15) for Q1 2025 (basic and diluted; YoY improvement).

**Business Highlights**

-   Clinical milestone: Began a randomized, placebo-controlled Phase 3 trial of IFx-2.0 with pembrolizumab in first-line metastatic Merkel cell carcinoma (initiated June 2025).
-   Pipeline expansion: Completed the acquisition of Kineta and added TBS-2025, a VISTA inhibitor, with plans for a randomized Phase 2 in mutNPM1 AML in combination with a menin inhibitor.
-   R&D focus shift: Increased headcount and R&D spend toward IFx-2.0 and TBS-2025 and discontinued advancement of IFx-3.0.
-   Capital and liquidity actions: Launched a $50M at-the-market program, a $50M revolving credit facility, and completed registered direct/private placements to fund planned development.
-   Operational scale-up: Outsourced clinical operations to CROs, secured third-party manufacturing, and expanded regulatory and commercial readiness activities.

Original SEC Filing: TuHURA Biosciences, Inc./NV \[ HURA \] - 10-Q - May. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [HURA.US](https://longbridge.com/en/quote/HURA.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)

## Related News & Research

- [Wormser Freres Gestion Has $269,000 Stock Holdings in Zoetis Inc. $ZTS](https://longbridge.com/en/news/288171037.md)
- [Clear Harbor Asset Management LLC Acquires 95,532 Shares of Pfizer Inc. $PFE](https://longbridge.com/en/news/288231231.md)
- [GRAIL Presents Positive PATHFINDER 2 Results Of Galleri MCED Test At ASCO 2026](https://longbridge.com/en/news/288228856.md)
- [TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update | HURA Stock News](https://longbridge.com/en/news/286615229.md)
- [Sobi to present new data on pegcetacoplan at ERA 2026](https://longbridge.com/en/news/288238139.md)